Trial Profile
Study on the Safety, Tolerability and Pharmacokinetics of Single and Multiple Administration of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Advanced breast cancer; Brain metastases; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors JenKem Technology
- 16 Nov 2021 Status changed from recruiting to completed.
- 25 Apr 2020 Status changed from planning to recruiting.
- 09 Mar 2016 New trial record